
Gabapentin Market By Dosage(Capsule, Tablet, Oral Solution), By Type(Generic, Branded), By Application(Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
-
42435
-
Dec 2023
-
179
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
- Gabapentin Market Size, Share, Trends Analysis
- Gabapentin Market Dynamics
- Gabapentin Market Segmentation Analysis
- Gabapentin Industry Segments
- Gabapentin Market Growth Opportunity
- Gabapentin Market Regional Analysis
- Gabapentin Industry By Region
- Gabapentin Market Share Analysis
- Gabapentin Industry Key Players
- Gabapentin Market's Recent Development
- Report Scope
Gabapentin Market size is expected to be approximately USD 5.7 Bn in 2032, up from USD 2.9 Bn as of 2022. This is increasing at a rate of (CAGR) 7.2% over the duration from 2023 until 2032.
Gabapentin is a medication that is an anticonvulsant that is used to treat epilepsy and neuropathy. It is a medicine that alters the functioning of the brain and nerves, which could result in seizures or unpleasant sensations. Gabapentin is a medication recommended by doctors to those suffering from nerve pain due to chemotherapy, as well as other ailments such as diabetes, shingles, or other situations.
The medication binds to calcium channels in the brain and spinal cord, reducing abnormal electrical signals. This helps to prevent seizures and dampen pain signals in conditions that involve hypersensitivity in the nervous system. Gabapentin has become a feasible alternative to treat many chronic pain conditions because it can ease nerve pain. However, it comes with minimal adverse side effects compared to other medicinal treatments.
Based on studies conducted by World Health Organization (WHO) epilepsy is a condition that affects more than 50 million people around the world. Within the United States, the prevalence of epilepsy-related disorders is estimated at 1.2 percent of the population, which is about 3.4 million.
Furthermore, the frequency of neuropathy discomfort in general is different in various studies. Based on an analysis of systematic studies in the field, the incidence of neuropathic pain was recorded as 3.3 percentage in Austria, 6.9% in France, and as high as 8% UK.
The Gabapentin Market is expected to see significant growth over the next decade driven by various elements. The aging of our population and the increase in the incidence of neuropathic pain conditions are the main elements that are responsible for the growth of the Gabapentin Market.
As the population of the world ages, growing, the risk of developing illnesses like shingles and diabetes which can lead to neuropathy, is rising. The increasing number of patients dependent on drugs like gabapentin is causing rapid growth in the market for Gabapentin Market.
Targeted R&D to widen therapeutic applications and refine gabapentin formulations also supports the steady expansion of the Gabapentin Market. Research to enable new gabapentin drug delivery mechanisms for improved absorption offers the potential to boost utilization further down the line as well. Together, demographic trends, improving diagnosis, and continued innovation converge to drive robust growth for the Gabapentin Market in the years ahead.
Lotus Pharmaceutical, in collaboration with Adalvo, has launched Gabapentin ER (Extended-Release) 300/600 mg in South Korea. This product, designed to provide long-lasting relief for individuals with Postherpetic Neuralgia (PHN), received approval from the Korean Ministry of Food and Drug Safety in March 2023.
Additionally, improved awareness and diagnosis rates for conditions that cause neuropathic pain are also positively impacting the Gabapentin Market. As doctors better recognize and identify nerve pain disorders, prescriptions for medications used in treatment like gabapentin have surged. With neuropathic conditions on the rise, the addressable patient population for the Gabapentin Market continues expanding rapidly.
Gabapentin Market Dynamics
Rising Seizures and Neuropathic Pain Incidence Bolster Gabapentin Market
The rising frequency of seizures and neuropathic pain is the primary reason that is driving the expansion of the Gabapentin Market. Gabapentin, which was initially developed to treat epilepsy. It has proved effective at treating neurological disorders which is a condition that is common and can be seen in a myriad of neurological conditions.
The growing prevalence of these illnesses worldwide partly due to factors like diabetes and shingles could result in a greater demand for effective treatment. This trend is expected to continue as the incidence of conditions causing neuropathic pain and seizures rises, signifying sustained market growth for gabapentin in managing these debilitating symptoms.
Technological Advancements and Generic Availability Expand Market
Technological advancements and the availability of generic versions of Gabapentin significantly contribute to its market growth. The development of generic versions has made the drug more accessible and affordable, leading to increased use. Additionally, advancements in pharmaceutical technology have improved the drug's formulation and delivery, enhancing its effectiveness and patient compliance.
This accessibility, coupled with improved drug delivery systems, is broadening the patient base for Gabapentin. The trend towards generic segment medication availability, combined with technological advancements, indicates a market that is becoming more inclusive and advanced, ensuring continued growth and wider adoption of Gabapentin.
Aging Population Drives Demand for Gabapentin
The rising geriatric population is one of the major drivers of Gabapentin. Gabapentin Market. Older people are more vulnerable to diseases such as postherpetic and neuropathic pain that are managed effectively with Gabapentin. As the world population age increasing the frequency of diseases that affect the elderly increases, which leads to an increase in demand for suitable medication.
Gabapentin's role in managing pain and seizures in the elderly makes it a crucial medication in geriatric care. The aging demographic trend suggests an ongoing rise in demand for Gabapentin, underlining its importance in addressing the healthcare needs of an aging population. This demographic shift is likely to sustain the market growth for Gabapentin, given its relevance in geriatric healthcare.
Side Effects and Potential for Abuse Restrain Gabapentin Market Growth
The growth of the Gabapentin market is being hindered by fears of its negative effects and the possibility of misuse. Gabapentin is a medicine used to treat neuropathy and also as an anticonvulsant has been associated with adverse reactions, such as fatigue, dizziness as well and peripheral edema. Additionally, there has been growing concern about the dangers of using it, particularly for those who have an addiction to substances.
These factors contribute to increased scrutiny and caution in prescribing practices. The apprehension among healthcare providers and patients regarding the side effects and abuse potential can lead to a preference for other medications, thereby limiting the expansion of the Gabapentin market.
Availability of Alternative Treatments Limits Gabapentin Market Growth
The availability of alternative treatments also poses a challenge to the growth of the Gabapentin market. As medical research advances various alternative therapies are available to treat conditions such as epilepsy and neuropathic pain. Alternatives include more modern anticonvulsant medicines that may have fewer negative side effects, non-pharmacological interventions as well and various treatment options for managing pain.
The presence of these alternatives gives patients and healthcare providers more options, potentially reducing the reliance on Gabapentin. This trend can lead to a decreased demand for Gabapentin, as the market for its primary indications becomes increasingly competitive with the introduction of alternative treatment modalities.
Gabapentin Market Segmentation Analysis
By Dosage Analysis
Gabapentin capsules represent the dominant dosage form in the market, favored for their convenience and patient compliance. The capsule form allows for flexible dosing, which is particularly important for titrating the optimal dose in conditions like epilepsy and neuropathic pain. Capsules are also preferred due to their ease of ingestion and the ability to mask the drug's taste, enhancing patient acceptability. The widespread use of capsules in various treatment regimens underscores their significance in the gabapentin market.
Tablets provide a viable alternative, especially for patients who have difficulty swallowing capsules. Their presence in the market ensures that patient preferences and physical limitations are accommodated. Oral solutions are essential for pediatric patients or those unable to ingest solid forms. This dosage form ensures that all patient demographics, including those with special needs, have access to gabapentin therapy.
By Type Analysis
Generic gabapentin holds a significant market share due to its cost-effectiveness compared to branded versions. After the expiration of the original patent, multiple generic versions have become available, making the medication more accessible to a broader patient base. The effectiveness of generic players gabapentin in managing various neurological conditions, coupled with its affordability, drives its dominant position in the market.
While branded gabapentin, such as Neurontin, initially led the market, its share has waned with the advent of generics. Nevertheless, branded versions maintain a market presence, supported by brand loyalty and the perception of higher efficacy among some patient groups.
By Application Analysis
Gabapentin's principal use is treating epilepsy. It is utilized as an adjunctive therapy to treat only partial seizures. Mechanism of Action, its safety profile, and its effectiveness in reducing seizures make it an essential component of epilepsy treatment. The increasing prevalence of epilepsy across the globe contributes to its dominance.
The drug is widely used to treat pain caused by neuropathic Gabapentin can help relieve ailments like diabetic neuropathy and postherpetic neuralgia. Its versatility, including uses in Restless Legs Syndrome and various off-label applications, diversifies its market application, enhancing its overall market expansion footprint.
By Distribution Channel Analysis
The hospital pharmacy segment leads in gabapentin distribution, primarily due to its use in managing acute episodes and initial treatment settings, like inpatient care for epilepsy. This channel's prominence is anchored in hospitals' critical role in treatment initiation and dose management.
Retail pharmacies are key for ongoing outpatient treatment, providing accessibility for continued gabapentin therapy. The growing trend of online pharmacies, favored for their convenience and competitive pricing, is reshaping the distribution landscape, offering an increasingly popular alternative for patients obtaining their medication.
Gabapentin Industry Segments
By Dosage
- Capsule
- Tablet
- Oral Solution
By Type
- Generic
- Branded
By Application
- Epilepsy
- Neuropathic Pain
- Restless Legs Syndrome
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Gabapentin Market Growth Opportunity
Growing Awareness and Adoption Offers Growth Opportunity in Gabapentin Market
The growing awareness and acceptance of Gabapentin, especially for use off-label, is an opportunity for growth in the market. The drug was created to treat epilepsy. Gabapentin is utilized for treating neuropathic pain, restless leg syndrome, and other ailments.
The increasing awareness by medical professionals as well as patients of its effectiveness in treating increasing concern of doctors and patients regarding its effectiveness in treating various disorders related to the nervous system and pain has resulted in a growth in use. This expansion is supported by the increasing number of studies conducted in clinical settings that demonstrate the effectiveness of Gabapentin. This is an indication of the growing demand for Gabapentin because of its therapeutic benefits.
Availability of Generic Versions Fuels Growth in Gabapentin Market
The availability of generic versions of Gabapentin significantly fuels market growth. Generic drugs, being more affordable than their branded counterparts, have increased the accessibility of Gabapentin to a wider patient base. The expiration of patents has led to the entry of multiple generic manufacturers, making the drug more cost-effective and widely available.
This trend is particularly important in markets where cost is a major barrier to accessing healthcare. The growing presence of generic Gabapentin aligns with the global push for cost-effective healthcare solutions, indicating a sustained expansion potential for the Gabapentin market.
Gabapentin Market Regional Analysis
North America Dominates with 38.20% Market Share
North America's substantial 38.20 percent share of the world Gabapentin Market can be attributed to the region's large number of diseases treated by gabapentin, including neuropathic seizures and pain. It is believed that the United States, in particular, is home to a significant affected by these ailments and contributes to the huge demands for Gabapentin. Additionally, the well-developed healthcare system and a high level of expenditure on healthcare allow for wide access to prescription drugs such as gabapentin.
The dynamics of the market that are taking place in North America are influenced by the rising incidence of chronic neurologic and physical pain throughout the world. Gabapentin, being a key therapeutic agent for these conditions, experiences strong demand. Additionally, the region's robust pharmaceutical industry and extensive distribution networks facilitate the availability and supply of gabapentin. The ongoing research into new therapeutic applications of gabapentin also plays a role in sustaining its market presence in North America.
Europe is A Market Driven by Healthcare Accessibility
Europe's gabapentin market is driven by the region's accessibility to healthcare and the prevalence of neurological and pain-related disorders. European countries, with their universal healthcare systems, ensure that patients have access to necessary medications like gabapentin. The region’s focus on mental health and neurological disorders supports the demand for gabapentin, used in the treatment of conditions such as anxiety disorders and neuropathic pain.
Asia-Pacific's Growing Market with Increasing Healthcare Focus
Within Asia-Pacific markets for gabapentin have been growing due to the increasing importance of the region to healthcare and the increasing rate of epilepsy as well as chronic pain. Countries like China as well as India are experiencing an increase in healthcare costs and improvement in the infrastructure for healthcare. This, coupled with the growing awareness of neurological disorders and their symptoms has led to a growing demand for gabapentin within this region and has helped position Asia-Pacific as a key developing market in this kind of drug.
Gabapentin Industry By Region
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
In the Gabapentin Market, primarily used for treating neuropathic pain and epilepsy, the companies listed play significant roles in manufacturing and distributing this medication globally. Zydus Pharmaceuticals, Inc. and Glenmark Pharmaceuticals Limited are key players, offering generic versions of Gabapentin, reflecting the market's focus on providing cost-effective alternatives to branded drugs.
Sun Pharmaceutical Industries Ltd. and Aurobindo Pharma, with their extensive global presence, are instrumental in ensuring the widespread availability of Gabapentin, catering to the growing demand for this therapeutic agent across different regions. Ascend Laboratories, LLC and Apotex Inc., known for their robust generic drug portfolios, contribute significantly to the market with their high-quality and affordable Gabapentin formulations.
Teva Pharmaceutical Industries Ltd. and Amneal Pharmaceuticals LLC, as major products generic pharmaceutical companies, play crucial roles in the market by offering a range of dosages and formulations, enhancing the drug's accessibility and patient compliance. Cipla USA, Inc. and BP Pharmaceuticals Laboratories Company, while smaller compared to global giants, provide specialized offerings in Gabapentin, catering to niche market segments.
Collectively, these companies drive the Gabapentin Market, representing a range of strategies from manufacturing generic versions to developing specialized formulations, crucial for addressing the diverse therapeutic needs associated with neuropathic pain and epilepsy.
Gabapentin Industry Key Players
- Zydus Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Limited
- Sun Pharmaceutical Industries Ltd.
- Ascend Laboratories, LLC
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma.Ltd
- Amneal Pharmaceuticals LLC.
- Cipla USA, Inc.
- BP Pharmaceuticals Laboratories Company
- Assertio Holdings, Inc.
- Arbor Pharmaceuticals, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals Inc.
- Jubilant Life Sciences Ltd.
- Lupin Ltd.
Gabapentin Market's Recent Development
- In May 2023, Research conducted at UC San Francisco provided new insights into how the widely prescribed medication Gabapentin works inside cells. This discovery opens up possibilities for more effective treatments for diseases such as epilepsy and Lupus.
- In March 2023, Granules India Ltd received approval from the US Food & Drug Administration (USFDA) for its generic gabapentin tablets. The approval covers Gabapentin tablets of strengths 600 mg and 800 mg.
- In February 2023, Sun Pharmaceutical Industries Ltd announced its plans to acquire a 27.4% stake in Remidio Innovative Solutions Pvt Ltd for ₹1.5 billion. This acquisition is set to be completed by the end of February
- In August 2022, A study was conducted at EIOH to evaluate the effectiveness of gabapentin, in combination with ibuprofen or acetaminophen, in managing dental pain after tooth extractions. Researchers treated over 7,000 patients at an urgent dental care clinic with various combinations of opioids, ibuprofen, acetaminophen, and gabapentin.
Report Scope
Report Features Description Market Value (2022) USD 2.9 Billion Forecast Revenue (2032) USD 5.7 Billion CAGR (2023-2032) 7.2% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Dosage(Capsule, Tablet, Oral Solution), By Type(Generic, Branded), By Application(Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Zydus Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC, Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC., Cipla USA, Inc., BP Pharmaceuticals Laboratories Company, Arbor Pharmaceuticals, Inc., Pfizer Inc., Amneal Pharmaceuticals Inc., Jubilant Life Sciences Ltd., Lupin Ltd. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
-
- Zydus Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Limited
- Sun Pharmaceutical Industries Ltd.
- Ascend Laboratories, LLC
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma.Ltd
- Amneal Pharmaceuticals LLC.
- Cipla USA, Inc.
- BP Pharmaceuticals Laboratories Company
- Assertio Holdings, Inc.
- Arbor Pharmaceuticals, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals Inc.
- Jubilant Life Sciences Ltd.
- Lupin Ltd.